APOL1-Mediated Kidney Disease
JAMA · 21.05.2024 · 331 (19) · 1668
DOI: 10.1001/jama.2024.2667 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 21.05.2024. Verfasst von Timothy Hopper und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina. Hauptthemen laut MEDLINE: Apolipoprotein L1, Black or African American, Renal Insufficiency, Chronic, Trypanosomiasis, African. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIMHD NIH HHS.
Abstract (Originalsprache)
This JAMA Insights reviews the origin of APOL1 high-risk genetic variants, defines APOL1-mediated kidney disease, and discusses recommendations for screening and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
- Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina.
Förderung
- NIDDK NIH HHS
- NIMHD NIH HHS
Zitieren
APA
Hopper, T., & Olabisi, O. A. (2024). APOL1-Mediated Kidney Disease. JAMA, 331(19), 1668. https://doi.org/10.1001/jama.2024.2667
Vancouver
Hopper T, Olabisi OA. APOL1-Mediated Kidney Disease. JAMA. 2024;331(19):1668. doi:10.1001/jama.2024.2667
BibTeX
@article{Hopper2024,
author = {Hopper, Timothy and Olabisi, Opeyemi A},
title = {APOL1-Mediated Kidney Disease},
journal = {JAMA},
year = {2024},
volume = {331},
number = {19},
pages = {1668},
doi = {10.1001/jama.2024.2667}
}
EUVIMED